Xiaolin Hou | Pharmacology | Best Researcher Award

Best Researcher Award

                 Xiaolin Hou
Affiliation Beijing University of Agriculture
Country China
Scopus ID 37045332600
Documents 61
Citations 1319
h-index 19
Subject Area Pharmacology
Event International Research Hypothesis Excellence Award
ORCID 0000-0003-4423-635X

Xiaolin Hou
Beijing University of Agriculture, China

Xiaolin Hou  the Best Researcher Award article presents an academic overview of Xiaolin Hou, a researcher affiliated with Beijing University of Agriculture, China. The profile highlights scholarly activities, publication output, and research impact indicators associated with the field of pharmacology and related interdisciplinary domains. The article further evaluates the research profile in the context of recognition through the International Research Hypothesis Excellence Award.[1]

Abstract

This article summarizes available scholarly information concerning Xiaolin Hou and evaluates academic metrics and research contributions associated with pharmacological investigations. Academic productivity indicators such as Scopus-indexed publications, citation metrics, and research visibility provide measurable evidence of scientific activity and scholarly engagement.[1]

Keywords

Pharmacology; Academic Research; Citation Analysis; Scholarly Impact; Scopus; Research Evaluation; Best Researcher Award

Introduction

Research evaluation frequently considers scientific productivity, publication quality, and measurable academic influence. Scholarly databases such as Scopus provide standardized metrics including h-index values and citation indicators for assessing research output.[2]

Research Profile

Xiaolin Hou is a professor and researcher at the College of Veterinary Medicine, Beijing University of Agriculture, China. His research focuses on veterinary pharmacology, animal disease prevention, pathogen detection, antimicrobial resistance, and viral infection mechanisms. He serves as an academic leader in Basic Veterinary Medicine and has contributed significantly to animal health and disease control research.

Research Contributions

The researcher demonstrates measurable contributions in pharmacology and scientific investigation through indexed publications and participation in academic dissemination activities. Research outcomes contribute to literature development and interdisciplinary knowledge exchange.[1]

Publications

Xiaolin Hou is a researcher and professor at Beijing University of Agriculture, China, specializing in veterinary medicine, pathogen biology, animal disease prevention, and antimicrobial research. His scholarly work includes numerous representative indexed studies available through international scientific databases, contributing significantly to veterinary pharmacology and infectious disease research.[3]

Research Impact

Citation indicators and h-index measurements are commonly employed to assess scholarly visibility and influence. Available metrics suggest substantial research engagement and dissemination within indexed academic environments.[2]

Award Suitability

The profile characteristics associated with Xiaolin Hou indicate alignment with evaluation categories commonly considered for academic distinction programs, including publication output, scholarly impact, citation metrics, and contribution to research communities.[4]

Conclusion

The presented academic profile summarizes institutional affiliation, publication metrics, and scholarly indicators associated with research productivity. Such indicators contribute to broader assessments used in academic recognition and research award programs.

References

  1. Elsevier. (n.d.). Scopus author details: Xiaolin Hou, Author ID 37045332600. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=37045332600
  2. DOI Foundation. Digital Object Identifier resource.
    https://doi.org/10.1016/j.phrs.2020.104850
  3. International Research Hypothesis Excellence Award Program. Award evaluation and recognition framework.
    https://researchhypothesis.com/
  4. Shen, R., Guo, J., Liu, X., Yin, P., & Hou, X. (2026). Forsythoside A inhibits avian infectious bronchitis virus infection by binding the S1 subunit. Virology. Advance online publication.

Liwu Fu | Pharmacology | Best Researcher Award

Prof. Liwu Fu | Pharmacology | Best Researcher Award

Professor at Sun Yat-sen University Cancer Center, China

Liwu Fu, PhD, MD is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University, Guangzhou, China. 🎓 He earned his MD from Guangdong Medical and Pharmaceutical College, followed by an MS and PhD in Medicine from Sun Yat-sen University. 🏥 Dr. Fu completed a postdoctoral fellowship at the Medical University of South Carolina, USA. His research focuses on anticancer drug development and cancer pathophysiology. 🔬 With extensive experience in oncology and toxicology, he has held key academic and research positions since 1987.

Publication Profile

Scopus

🎓 Educational Background

📌 Liwu Fu has a strong academic foundation in medicine and cancer research. He earned his MD from Guangdong Medical and Pharmaceutical College (1987) 🏥. He then pursued an MS in Medicine (1993) and a PhD in Medicine (1996) at Sun Yat-sen University, specializing in toxicology and cancer research 🔬. Further advancing his expertise, he completed a postdoctoral fellowship (1999-2002) at the Medical University of South Carolina, USA, in pathology and laboratory medicine 🧬. His extensive education has shaped his contributions to oncology and anticancer drug development. 🎗️

💼 Professional Experience

🔬 Liwu Fu is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University (since 2002) 🏥. He previously served as an Associate Professor (1998-2002) and Lecturer, Deputy Head (1996-1998) in the Department of Anticancer Drug. His research was further enriched by a postdoctoral fellowship at the Medical University of South Carolina, USA (1999-2002) 🇺🇸. He has held key leadership roles, including Chairman of the Guangdong Cancer Pharmacological Society (since 2009) and Associate Director in multiple national cancer and pharmacology organizations 🎗️. He is also an AACR member and has contributed significantly to cancer pharmacology. 🚀

Research Focus

Dr. Liwu Fu’s research focuses on cancer biology 🔬, particularly in tumor immunology 🧬, drug resistance mechanisms 💊, and targeted therapies 🎯. His studies explore immune evasion through PD-L1 regulation, the role of extracellular vesicles in chemoresistance, and cancer stem cell-derived signals. He has contributed significantly to understanding lung cancer 🫁, colorectal cancer 🏥, and leukemia 🧑‍⚕️. His work also investigates innovative drug strategies like ERK and KRAS inhibitors, enhancing immune checkpoint therapies. His publications in high-impact journals demonstrate expertise in molecular oncology 🧫 and precision medicine 🏹, making key advancements in overcoming cancer treatment resistance.

Publication Top Notes

📌 Intra-tumoral Sphingobacterium multivorum Promotes Triple-Negative Breast Cancer Progression by Suppressing Tumor Immunosurveillance
🗓 Year: 2025 |  Cited by: 2 |  Molecular Cancer

📌 Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion
🗓 Year: 2025 | Advanced Science

📌 Resistance to Antibody–Drug Conjugates: A Review
🗓 Year: 2025 | Acta Pharmaceutica Sinica B

📌 PBA2, a Novel Inhibitor of the β-Catenin/CBP Pathway, Eradicates Chronic Myeloid Leukemia Including BCR-ABL T315I Mutation
🗓 Year: 2024 | Molecular Cancer

📌 BI-2865, a Pan-KRAS Inhibitor, Reverses the P-Glycoprotein Induced Multidrug Resistance In Vitro and In Vivo
🗓 Year: 2024 |  Cited by: 2 |  Cell Communication and Signaling

Conclusion

Professor Liwu Fu is a distinguished cancer researcher specializing in pharmacology, chemotherapy, multidrug resistance, and personalized cancer therapy. With over 200 publications in high-impact SCI journals and leadership in 40+ major research projects, his contributions to oncology are widely recognized. He has received prestigious honors, including the Chinese Anti-Cancer Association Science and Technology Award, and holds key roles in national and international cancer research organizations. Additionally, he serves on the editorial boards of top-tier cancer research journals and reviews for esteemed publications like Cancer Research and Journal of Pharmacology and Experimental Therapeutics. His groundbreaking work in overcoming multidrug resistance positions him as a strong candidate for the Best Researcher Award. 🚀🏆